Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline landscape.

Muscle-invasive disease is a type of bladder cancer which is much more likely to spread to other parts of the body Symptoms includes blood in the urine and pain when passing urine. Risk factors include use of tobacco, family history, exposure to arsenic, and infections. Treatment includes removing the bladder or treating the bladder with radiation and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Muscle Invasive Bladder Cancer (MIBC).

Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Invasive Bladder Cancer (MIBC) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Muscle Invasive Bladder Cancer (MIBC) Overview 7
Therapeutics Development 8
Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Overview 8
Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis 9
Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Development by Companies 10
Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Investigation by Universities/Institutes 11
Muscle Invasive Bladder Cancer (MIBC) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Muscle Invasive Bladder Cancer (MIBC) - Products under Development by Companies 15
Muscle Invasive Bladder Cancer (MIBC) - Products under Investigation by Universities/Institutes 16
Muscle Invasive Bladder Cancer (MIBC) - Companies Involved in Therapeutics Development 17
Argos Therapeutics Inc 17
Astellas Pharma Inc 18
Astex Pharmaceuticals Inc 19
AstraZeneca Plc 20
Cold Genesys Inc 21
F. Hoffmann-La Roche Ltd 22
MedImmune LLC 23
Oncolytics Biotech Inc 24
Sillajen Biotherapeutics 25
Taris Biomedical LLC 26
Muscle Invasive Bladder Cancer (MIBC) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
atezolizumab - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
AZD-1775 + durvalumab - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
AZD-4547 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Cellular Immunotherapy for Oncology - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
CG-0070IT - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
durvalumab - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
erlotinib hydrochloride - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
gemcitabine hydrochloride - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
guadecitabine - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
MTG-202 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
pelareorep - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
pexastimogene devacirepvec - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
rocapuldencel-T - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects 104
Muscle Invasive Bladder Cancer (MIBC) - Product Development Milestones 105
Featured News & Press Releases 105
Jul 13, 2016: TARIS Biomedical Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS) in Patients with Muscle-Invasive Bladder Cancer 105
Jun 08, 2015: Oncolytics Biotech Provides Update at AGM on Planned Registration Program for REOLYSIN 105
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

List of Tables

Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016 8
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Argos Therapeutics Inc, H2 2016 17
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astellas Pharma Inc, H2 2016 18
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 19
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by AstraZeneca Plc, H2 2016 20
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Cold Genesys Inc, H2 2016 21
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 22
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by MedImmune LLC, H2 2016 23
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Oncolytics Biotech Inc, H2 2016 24
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Sillajen Biotherapeutics, H2 2016 25
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Taris Biomedical LLC, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Assessment by Combination Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects, H2 2016 104